Hong KongZhonghui Biotech’s shares cannot trade since 1 April.
The 2025 listing drew over 4,000 times oversubscription, and a third director has resigned this year.
Auditor Deloitte questioned HK$272 million in fund purchases and HK$58 million in advisory fees, then resigned on 13 April.
The company says its business remains substantive and viable, and two forensic investigations have not reported.
The exchange’s 6 conditions for resuming trading include forensic findings and the overdue 2025 annual report.
How each outlet framed it
- TMTPost leans critical
- reconstructs the governance unravelling: three board departures in 2026, Deloitte's audit resignation over HK$272M fund round-trips and HK$58M in advisory fees
Sources: TMTPost